false
Catalog
2023 World Conference on Lung Cancer (Posters)
P1.23. Liquid Biopsy Predicts Differential Benefit ...
P1.23. Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer - PDF(Abstract)
Back to course
Pdf Summary
This study presented at the WCLC 2023 conference investigated the use of liquid biopsy as a predictive marker for the clinical benefit of first-line pembrolizumab treatment in advanced non-small cell lung cancer (aNSCLC) patients. The study enrolled aNSCLC patients who were treated with pembrolizumab and performed liquid biopsies at baseline and after three weeks of treatment. The liquid biopsies were evaluated for cell free DNA (cfDNA) quantification and analyzed for tumor-associated genetic alterations using a NGS panel.<br /><br />The results showed that patients who had higher levels of tumor-associated genetic alterations at baseline had a worse response to pembrolizumab treatment. Additionally, patients who experienced early death or had worse progression-free survival and overall survival had higher levels of tumor-associated genetic alterations at the second liquid biopsy. These findings suggest that liquid biopsy can predict the outcome of pembrolizumab treatment, even in patients with high levels of PDL-1 expression.<br /><br />The study concludes that liquid biopsy can be used as a tool to customize first-line treatment strategies for aNSCLC patients. By identifying patients who are likely to derive detrimental effects from pembrolizumab treatment, liquid biopsy can help optimize treatment decisions and potentially improve patient outcomes.<br /><br />Overall, this study highlights the potential of liquid biopsy as a predictive marker in immunotherapy for aNSCLC patients, providing valuable insights for personalized treatment approaches.
Asset Subtitle
Laura Bonanno
Meta Tag
Speaker
Laura Bonanno
Topic
Pathology & Biomarkers: Liquid Based Biomarkers
Keywords
liquid biopsy
predictive marker
first-line pembrolizumab treatment
advanced non-small cell lung cancer
aNSCLC
cell free DNA
tumor-associated genetic alterations
NGS panel
progression-free survival
overall survival
×
Please select your language
1
English